1. Introduction {#sec1}
===============

As the most common type of lung cancer and a non-small cell lung carcinoma (NSCLC) \[[@B1]\], lung adenocarcinoma (LAC) is characterized by gland or duct formation and massive mucus production \[[@B2]\]. LAC generally originates in peripheral lung tissue, and this is in contrast with squamous cell lung cancer and small cell lung cancer (SCLC), which are both apt to be located more centrally in lungs \[[@B3], [@B4]\]. In US, LAC accounts for approximately 40% of lung cancers \[[@B5]\]. Smoking is the main cause of LAC, and the disease has a high metastasis rate even at an early stage \[[@B4]\]. Therefore, it is necessary to identify key genes in LAC and develop effective therapeutic schedule.

The WNT/TCF signaling can promote osseous and brain metastasis of LAC cells through targeting*HOXB9* and*LEF1*which mediates chemotactic invasion and colony outgrowth \[[@B6]\]. Coexpression of*Oct4* and*Nanog*, which are homeobox transcription factors important for self-renewal of stem cells, commands epithelial-mesenchymal transdifferentiation, mediates tumor-initiating ability, and contributes to metastasis of LAC \[[@B7]\]. As a noncoding RNA,*MALAT-1* enhances motility of LAC cells via regulating motility-associated gene expression in transcriptional and posttranscriptional levels \[[@B8], [@B9]\].*BRAF* mutation is frequently detected in human LAC, indicating that*BRAF* may serve as a therapeutic target for a subset of patients with the disease \[[@B10], [@B11]\]. Overexpression of*caveolin-1* is essential for mediating filopodia formation, which may promote invasion of LAC cells \[[@B12]\]. In spite of the above researches, the mechanisms of LAC still remain unclear.

Recently, along with the development of chip technology, microarray data have been obtained and uploaded to Gene Expression Omnibus (GEO) for us to study \[[@B13]\]. Using microarray data GSE62950, we screened the differentially expressed genes (DEGs) between LAC tissue samples and adjacent normal tissue samples. And their potential functions were predicted by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Disease Ontology (DO) enrichment analysis. Then, the interrelationships between these DEGs were analyzed by protein-protein interaction (PPI) network and module analysis. At last, LAC-associated methylation sites were identified and mapped to the DEGs to obtain LAC-associated DEGs.

2. Materials and Methods {#sec2}
========================

2.1. Microarray Data {#sec2.1}
--------------------

Microarray data GSE62950 was downloaded from the database of GEO (<http://www.ncbi.nlm.nih.gov/geo/>), which included a DNA methylation dataset and an mRNA expression profiles dataset. The DNA methylation dataset and the mRNA expression profiles dataset separately were based on the platform of GPL8432 Illumina HumanRef-8 WG-DASL v3.0 and GPL8490 Illumina HumanMethylation27 BeadChip (HumanMethylation27_270596_v.1.2), and both of them included 28 LAC tissue samples and 28 adjacent normal tissue samples.

2.2. Data Preprocessing {#sec2.2}
-----------------------

Normalized series matrix file of mRNA expression profiles was downloaded directly. After beta matrix of DNA methylation data was downloaded, primary methylation signals were preprocessed by Methylation Module V1.9 \[[@B14]\] in BeadStudio V3.1.0.0 to obtain normalized beta matrix. Those methylation sites which had no signal values in one or more samples were removed.

2.3. DEGs Screening {#sec2.3}
-------------------

Using Limma package \[[@B15]\] in R, the DEGs between LAC tissue samples and adjacent normal tissue samples were identified. The *p* values of DEGs were adjusted by Benjamini-Hochberg (BH) method \[[@B16]\]. The adjusted *p* value \< 0.05 and \|log~2~⁡fold-change(FC) \| ≥1 were taken as the thresholds.

2.4. GO, KEGG, and DO Enrichment Analysis {#sec2.4}
-----------------------------------------

GO is utilized for predicting potential functions of gene products in three categories (biological process, BP; cellular component, CC; and molecular function, MF) \[[@B17]\]. The KEGG database can be used for systematic analysis of gene functions, which connects genomic information with corresponding functional information \[[@B18]\]. The DO database contains a comprehensive knowledge of human diseases and is applied to annotate diseases \[[@B19]\]. Using TargetMine online tool \[[@B20]\], GO, KEGG, and DO enrichment analyses were performed for the DEGs. The *p* values of enriched terms were corrected by Holm-Bonferroni \[[@B21]\]. The adjusted *p* value \< 0.05 was used as the cut-off criterion.

2.5. PPI Network and Module Construction {#sec2.5}
----------------------------------------

The STRING \[[@B22]\] database was utilized to search PPI pairs among the DEGs. And combined score \> 0.4 was used as the cut-off criterion. Then, the PPI network of the DEGs was visualized by Cytoscape (<http://www.cytoscape.org/>) \[[@B23]\]. Subsequently, igraph package \[[@B24]\] in R was used to calculate connectivity degrees of nodes (proteins) in the PPI network, and nodes with higher degrees were taken as hub nodes.

Furthermore, MCODE plugin \[[@B25]\] in Cytoscape was used to screen modules from the PPI network. Using BinGO plugin \[[@B26]\], GO functional enrichment analysis was conducted for the genes in each module.

2.6. Screening of LAC-Associated Methylation Sites {#sec2.6}
--------------------------------------------------

Using genefilter package \[[@B27]\] in R, the methylation sites which had higher beta value variations within groups compared with variations among groups were deleted. And the *p* value \< 0.05 was used as the cut-off criterion. Then, the methylation sites located in sex chromosomes were removed. Finally, the associations between the screened methylation sites and LAC were analyzed by CpGassoc package \[[@B28]\] in R. The *p* value \< 0.05 was taken as the threshold.

2.7. Correlation Analysis of Methylation Sites and DEGs {#sec2.7}
-------------------------------------------------------

According to the annotation information of the DNA methylation profiles, the nearest genes to the LAC-associated methylation sites were obtained and then mapped to the DEGs. At last, LAC-associated methylation sites of the DEGs were gained.

2.8. Validation of Methylation Sites and DEGs in LAC Tissue Samples {#sec2.8}
-------------------------------------------------------------------

The RNASeqV2 data of LAC were downloaded from The Cancer Genome Atlas (TCGA, <http://cancergenome.nih.gov/>) database, which included 515 LAC tissue samples and 59 adjacent normal tissue samples. Using Limma package \[[@B15]\] in R, the DEGs with the adjusted *p* value \< 0.05 and \|log~2~FC\| ≥ 1 were also screened. Meanwhile, the methylation data of LAC were also downloaded from TCGA database, which included 459 LAC tissue samples and 32 adjacent normal tissue samples. Moreover, LAC-associated methylation sites were also identified and mapped to the DEGs using the same methods as the above.

3. Results {#sec3}
==========

3.1. Data Preprocessing and DEGs Screening {#sec3.1}
------------------------------------------

After preprocessing, total 18626 beta values of DNA methylation data and 18626 gene expression values of mRNA expression profiles separately were obtained. Compared with adjacent normal tissue samples, there were a total of 913 DEGs (including 409 upregulated and 504 downregulated genes) in LAC tissue samples. In the heat map of the DEGs, LAC tissues could be definitely separated from adjacent normal tissues by the DEGs ([Figure 1](#fig1){ref-type="fig"}).

3.2. GO, KEGG, and DO Enrichment Analysis {#sec3.2}
-----------------------------------------

Using TargetMine online tool, functions of the DEGs were predicted by GO, KEGG, and DO enrichment analyses. For the upregulated genes, the enriched GO functions included multicellular organismal catabolic process (*p* value = 8.59*E* − 07) in BP category, as well as extracellular region (*p* value = 2.67*E* − 04) and extracellular space (*p* value = 0.002024) in CC category ([Table 1(a)](#tab1){ref-type="table"}). The enriched KEGG pathways for upregulated genes included protein digestion and absorption (*p* value = 0.001244) and cell cycle (*p* value = 0.026338, which involved cell division cycle 20,*CDC20*; cyclin B2,*CCNB2*; and mitotic arrest deficient 2-like 1,*MAD2L1*) ([Table 1(b)](#tab1){ref-type="table"}). The enriched DO terms for upregulated genes included cell type cancer (adjust. *p* value = 6.12*E* − 05), germ cell cancer (adjust. *p* value = 0.001326), embryoma (adjust. *p* value = 0.008727), and embryonal cancer (adjust. *p* value = 0.009481) ([Table 1(c)](#tab1){ref-type="table"}). And all of the DO terms involved*MAD2L1* and aurora B kinase (*AURKB*). The enriched GO functions for downregulated genes were listed in [Table 1(d)](#tab1){ref-type="table"}, including single-organism process (*p* value = 5.73*E* − 05) and single-multicellular organism process (*p* value = 1.93*E* − 04, which involved wingless-related MMTV integration site 3A,*WNT3A*) in BP category, as well as cell periphery in CC category (*p* value = 1.03*E* − 05, which involved*WNT3A*). In addition, there were nonsignificant KEGG pathways and DO terms enriched for the downregulated genes.

3.3. PPI Network and Module Analysis {#sec3.3}
------------------------------------

PPI networks for upregulated and downregulated genes were constructed, respectively. The PPI network for upregulated genes had 229 nodes and 725 interactions ([Figure 2(a)](#fig2){ref-type="fig"}). Particularly,*MAD2L1* (degree = 36),*AURKB* (degree = 38),*CCNB2* (degree = 40), and*CDC20* (degree = 42) had higher degrees, and they can interact with each other in the PPI network. Several modules were screened from the PPI network for upregulated genes, and the largest module (module 1) is also showed in [Figure 2(b)](#fig2){ref-type="fig"}. GO functional enrichment analysis showed that the genes in module 1 were involved in mitosis-associated terms.

The PPI network for downregulated genes had 233 nodes and 368 interactions ([Figure 3](#fig3){ref-type="fig"}). Connectivity degrees of the nodes in the PPI network were calculated, and cGMP-dependent protein kinase II (*PRKG2*, degree = 11), VE-cadherin (*CDH5*, degree = 12),*WNT3A* (degree = 15), adenylyl cyclase 8 (*ADCY8*, degree = 16), and adenylyl cyclase 4 (*ADCY4*, degree = 17) were the top 5 nodes which had higher degrees. What is more, nonsignificant modules were screened from the PPI network for downregulated genes.

3.4. Screening of LAC-Associated Methylation Sites {#sec3.4}
--------------------------------------------------

After screening, total 8856 methylation sites were obtained. Then, the associations between the screened methylation sites and LAC were analyzed under the threshold of *p* value \< 0.05. As a result, 230 LAC-associated methylation sites were identified.

3.5. Correlation Analysis of Methylation Sites and DEGs {#sec3.5}
-------------------------------------------------------

There were 29 LAC-associated methylation sites located in 27 DEGs (e.g., Src homology 3 domain GRB2-like 2,*SH3GL2*; brain-specific angiogenesis inhibitor 3,*BAI3*; H-cadherin,*CDH13*; junctional adhesion molecule 2,*JAM2*; metallothionein 1A,*MT1A*; LIM-homeobox containing 6,*LHX6*; and insulin-like growth factor binding protein-3,*IGFBP3*) ([Table 2](#tab2){ref-type="table"}). And all of the methylation sites were within 2 kb from transcriptional start sites (TSSs) of the DEGs. For the 29 methylation sites, their methylation indexes in LAC tissue samples were compared with that in adjacent normal tissue samples. The methylation indexes of 19 methylation sites were significantly increased, and the downstream genes mediated by those 19 methylation sites were downregulated. Nevertheless, 1 methylation site had significantly decreased methylation index, and its downstream genes were upregulated.

3.6. Validation of Methylation Sites and DEGs in LAC Tissue Samples {#sec3.6}
-------------------------------------------------------------------

Total 4893 DEGs (including 2191 upregulated genes and 2702 downregulated genes) were identified in the LAC sample data downloaded from TCGA database. There were 691 common DEGs (including 310 upregulated genes and 381 downregulated genes) between the 4893 DEGs identified in the LAC sample data downloaded from TCGA database and the 913 DEGs identified in the microarray data of GSE62950. The common DEGs included genes such as*WNT3A*,*MAD2L1*,*AURKB*,*CCNB2*,*CDC20*,*SH3GL2*,*BAI3*,*CDH13*,*JAM2*,*MT1A,* and*IGFBP3*. In addition, the 29 LAC-associated methylation sites identified in the microarray data of GSE62950 were also detected in the methylation data downloaded from TCGA database.

4. Discussion {#sec4}
=============

In this study, 913 DEGs including 409 upregulated and 504 downregulated genes were identified in LAC tissue samples compared with adjacent normal tissue samples. Total 230 LAC-associated methylation sites were identified, among which 29 LAC-associated methylation sites were located in 27 DEGs. Afterwards, the RNASeqV2 data and methylation data of LAC were downloaded from TCGA database to validate the obtained methylation sites and DEGs. There were 691 common DEGs (such as*WNT3A*,*MAD2L1*,*AURKB*,*CCNB2*,*CDC20*,*SH3GL2*,*BAI3*,*CDH13*,*JAM2*,*MT1A,* and*IGFBP3*) between the 913 DEGs identified in the microarray data of GSE62950 and the 4893 DEGs identified in the LAC sample data downloaded from TCGA database. In addition, the 29 LAC-associated methylation sites identified in the microarray data of GSE62950 were also detected in the methylation data downloaded from TCGA database. Functional enrichment indicated that*WNT3A* was involved in single-multicellular organism process and cell periphery. Overexpression of*Wnt5a*, which belongs to*Wnt* family that encodes signaling glycoproteins, promotes invasion of NSCLC during tumor progression \[[@B29], [@B30]\]. Via activating JNK pathway,*Wnt-7a* and*Fzd-9*signaling plays role in inducing the receptor tyrosine kinase inhibitor Sprouty-4 and cadherin proteins and is essential for maintaining epithelial differentiation and inhibiting transformed cell growth in some NSCLC patients \[[@B31]\]. In the PPI network for downregulated genes, WNT3A had higher degrees. These suggested that WNT3A might play a role in LAC.

Besides,*CDC20*,*CCNB2,* and*MAD2L1* were enriched in the pathway of cell cycle. Meanwhile,*MAD2L1* and*AURKB* were involved in DO terms of type cancer, germ cell cancer, embryoma, and embryonal cancer. Results of immunohistochemistry suggest that*CDC20* can be a negative marker in prognosis of patients with resected NSCLC, especially adenocarcinoma \[[@B32]\]. Overexpressed*CDK5RAP3* and*CCNB2*, as well as suppressed RAGE, may be promising biomarkers in lung adenocarcinoma \[[@B33]\]. The 5-year overall survival rates of LAC patients with low*CCNB2* mRNA levels were significantly higher than that with high levels, and overexpressed*CCNB2* mRNA can independently predict a poor prognosis in patients with LAC \[[@B34], [@B35]\]. Immunohistochemical analysis indicates*AURKB*, which mediates chromosome segregation during mitosis, is frequently overexpressed in primary lung carcinomas \[[@B36], [@B37]\]. Immunohistochemistry shows that overexpression of cell division cycle associated 8 (*CDCA8*) and*AURKB* can result in bad outcome of lung cancer patients; thus, suppression of the CDCA8-AURKB pathway is a potential therapeutic strategy for lung cancer \[[@B38]\]. Semiquantitative RT-PCR shows that mitotic arrest defective protein 2 (*MAD2*) is overexpressed in a high percentage of lung cancers, and multivariate analysis suggests that high-level*MAD2* can be a prognostic marker independently \[[@B39]\]. In the PPI network for upregulated genes,*MAD2L1*,*AURKB*,*CCNB2,* and*CDC20* had higher degrees, and they can interact with each other. Therefore,*MAD2L1*,*AURKB*,*CCNB2,* and*CDC20* might be implicated in LAC by interacting with each other.

Additionally, LAC-associated methylation sites were identified and mapped to the DEGs. And there were 29 LAC-associated methylation sites located in 27 DEGs (e.g.,*SH3GL2*,*BAI3*,*CDH13*,*JAM2*,*MT1A*,*LHX6,* and*IGFBP3*). Loss of*SH3GL2* is frequently detected in NSCLC and*SH3GL2* can mediate cellular growth and invasion through interacting with*EGFR* \[[@B40]\].*CDX2*,*VIL1,* and*BAI3*levels have significant differences in SCLC and large-cell neuroendocrine lung carcinoma (LCNEC); therefore, they can be diagnostic markers of these tumor types \[[@B41]\]. Tumor suppressor gene*CDH13*, located on chromosome 16q24.2--3, is downregulated in lung cancer and its aberrant methylation may be a potential marker for cancer detection \[[@B42]--[@B44]\]. Via mediating *β*1 integrin subunit and ERK activation in human dermal lymphatic endothelial cells (HDLEC), junctional adhesion molecule-C (*JAM-C*) contributes to lymphangiogenesis and nodal metastasis, suggesting that*JAM-C* may be a target for treating lymphatic metastases in NSCLC \[[@B45]\]. Overexpression of metallothionein (*MT*) can be used as an independent predictor of short-term survival in SCLC patients enduring chemotherapy \[[@B46], [@B47]\]. Previous study indicates that*LHX6* is a candidate tumor suppressor gene that has epigenetic silencing in patients with lung cancer \[[@B48]\]. In NSCLC, methylation status of*IGFBP-3* before cisplatin therapy seems to be a biomarker of prognosis, helping to select appropriate therapeutic method for patients \[[@B49], [@B50]\]. These declared that*SH3GL2*,*BAI3*,*CDH13*,*JAM2*,*MT1A*,*LHX6,* and*IGFBP3* might relate to LAC.

In conclusion, we carried out a comprehensive bioinformatics analysis to screen LAC-associated genes. We identified 913 DEGs and 8856 methylation sites in LAC tissue samples. Besides, LAC might correlate with several key genes (e.g.,*WNT3A*,*MAD2L1*,*AURKB*,*CCNB2*,*CDC20*,*SH3GL2*,*BAI3*,*CDH13*,*JAM2*,*MT1A*,*LHX6,* and*IGFBP3*). However, these bioinformatic findings need to be validated by further researches.

Additional Points
=================

*Highlights*. (1) We screened 913 DEGs and 8856 methylation sites in LAC tissue samples. (2) In the PPI networks,*MAD2L1*,*AURKB*,*CCNB2*,*CDC20,* and*WNT3A* had higher degrees. (3) There were 29 LAC-associated methylation sites located in 27 DEGs.
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![The heat map of the DEGs. Yellow and blue bars represent upregulated and downregulated genes, respectively. Two-way clustering results in the left side indicate that DEGs were clustered into three categories. Yellow and blue columns represent upregulated genes in lung adenocarcinoma tissues, while red column stands for downregulated genes.](BMRI2016-4369431.001){#fig1}

![The PPI network and module for upregulated genes. (a) The PPI network for upregulated genes. (b) Module 1 of the PPI network for upregulated genes. Red nodes represent upregulated genes. Thickness of edges is in direct proportion to combined scores. Node sizes are positively correlated with connectivity degrees of nodes.](BMRI2016-4369431.002){#fig2}

![The PPI network for downregulated genes. Green nodes represent downregulated genes. Thickness of edges is in direct proportion to combined scores. Node sizes are positively correlated with connectivity degrees of nodes.](BMRI2016-4369431.003){#fig3}

###### 

The GO functions, KEGG pathways, and DO terms separately enriched for upregulated and downregulated genes. (a) The top 5 GO functions enriched for upregulated genes. (b) The KEGG pathways enriched for upregulated genes. (c) The DO terms enriched for upregulated genes. (d) The top 5 GO functions enriched for downregulated genes.

  Category   ID           Description                                                Count   Gene symbol                        *p* value
  ---------- ------------ ---------------------------------------------------------- ------- ---------------------------------- --------------
  BP         GO:0044243   Multicellular organismal catabolic process                 15      *ACE2*, *COL10A1*, *COL11A1*,...   8.59*E* − 07
  BP         GO:0030574   Collagen catabolic process                                 14      *FAP*, *MMP1*, *MMP10*,...         4.49*E* − 06
  BP         GO:1903047   Mitotic cell cycle process                                 41      *ANLN*, *AURKB*, *BUB1*,...        1.70*E* − 05
  BP         GO:0044259   Multicellular organismal macromolecule metabolic process   15      *ACE2*, *COL10A1*, *COL11A1*,...   4.16*E* − 05
  BP         GO:0007067   Mitotic nuclear division                                   22      *ANLN*, *AURKB*, *CDC20*,...       4.57*E* − 05
  CC         GO:0005576   Extracellular region                                       122     *ACE2*, *ACOT11*, *ACY3*,...       2.67*E* − 04
  CC         GO:0005615   Extracellular space                                        46      *ACE2*, *AGR2*, *BPIFA1*,...       0.002024

  ID         Description                        Count   Gene symbol                        *p* value
  ---------- ---------------------------------- ------- ---------------------------------- -----------
  hsa04974   Protein digestion and absorption   11      *ACE2*, *COL10A1*, *COL11A1*,...   0.001244
  hsa04110   Cell cycle                         11      *CDC20*, *MAD2L1*, *CCNB2*,...     0.026338

  DOID           Description        Count   Gene symbol                     Adjust. *p* value
  -------------- ------------------ ------- ------------------------------- -------------------
  DOID:0050687   Cell type cancer   64      *AURKB*, *MAD2L1*, *ASPM*,...   6.12*E* − 05
  DOID:2994      Germ cell cancer   41      *AURKB*,*MAD2L1*, *CA9*,...     0.001326
  DOID:4766      Embryoma           38      *AURKB*, *BUB1*, *MAD2L1*,...   0.008727
  DOID:688       Embryonal cancer   38      *AURKB*,*MAD2L1*, *CA9*,...     0.009481

  Category   ID           Description                              Count   Gene symbol                       *p* value
  ---------- ------------ ---------------------------------------- ------- --------------------------------- --------------
  BP         GO:0044699   Single-organism process                  296     *AADAC*, *ABCB1*, *ABCG2*,...     5.73*E* − 05
  BP         GO:0044707   Single-multicellular organism process    150     *WNT3A*, *ACVRL1*, *ADCY4*,...    1.93*E* − 04
  BP         GO:0003013   Circulatory system process               24      *ACVRL1*, *ADRA1A*, *ADRB1*,...   4.58*E* − 04
  BP         GO:0032501   Multicellular organismal process         152     *WNT3A*, *ACVRL1*, *ADCY4*,...    0.001393
  BP         GO:0008015   Blood circulation                        23      *ACVRL1*, *ADRA1A*, *ADRB1*,...   0.001693
  CC         GO:0031226   Intrinsic component of plasma membrane   72      *ACVRL1*, *ADRA1A*, *ADRB1*,...   2.38*E* − 06
  CC         GO:0005886   Plasma membrane                          139     *WNT3A*, *ADCY8*, *ADGRB3*,...    8.04*E* − 06
  CC         GO:0071944   Cell periphery                           140     *WNT3A*, *ANXA8*, *AQP10*,...     1.03*E* − 05
  CC         GO:0044459   Plasma membrane part                     86      *AGER*, *AGTR1*, *AQP10*,...      1.44*E* − 05
  CC         GO:0005887   Integral component of plasma membrane    68      *FZD4*, *GHR*, *GP9*,...          1.75*E* − 05

###### 

The 29 lung adenocarcinoma-associated methylation sites located in 27 DEGs.

  IllumID      Chromosome   Meth.pos (Genome Build 36)   DEG          Distance_to_TSS   log~2~⁡FC⁡(DEG)   log~2~⁡FC⁡(β)
  ------------ ------------ ---------------------------- ------------ ----------------- ----------------- ---------------
  cg17398595   chr9         17568725                     *SH3GL2*     469               −2.461984643      0.419097018
  cg01817029   chr12        70951777                     *TRHDE*      953               −2.080720357      0.379725667
  cg18182399   chr2         219991419                    *DES*        76                −1.912270714      0.648411911
  cg01532771   chr19        7733560                      *CLEC4M*     521               −1.867543929      0.109407145
  cg17407908   chr6         32261093                     *AGER*       1092              −1.805516071      −0.076347441
  cg21057494   chr3         45041975                     *CLEC3B*     799               −1.784051786      0.176075101
  cg08555612   chr3         71917330                     *PROK2*      428               −1.734814286      0.599490205
  cg04884908   chr2         72228348                     *CYP26B1*    123               −1.568955357      0.541885215
  cg06615154   chr1         151789177                    *S100A3*     819               −1.430114286      0.141081243
  cg10244047   chr6         69402835                     *BAI3*       1323              −1.417121429      0.364653419
  cg18343862   chr11        10546579                     *XLKD1*      276               −1.346532857      0.053465056
  cg01880569   chr16        81217829                     *CDH13*      250               −1.329384643      0.115405772
  cg08977371   chr16        81217991                     *CDH13*      88                −1.329384643      0.396503001
  cg24829483   chr4         14950739                     *C1QTNF7*    29                −1.192036429      0.119720772
  cg08448751   chr3         52454641                     *SEMA3G*     558               −1.143811071      0.044592487
  cg03382304   chr21        25934047                     *JAM2*       587               −1.120553571      0.697781695
  cg02992632   chr3         193928074                    *FGF12*      8                 −1.1105825        0.296886805
  cg09137696   chr16        55229916                     *MT1A*       163               −1.0697075        0.541279943
  cg03192737   chr3         192413893                    *OSTN*       877               −1.036060357      0.126389084
  cg10031651   chr3         46596690                     *LRRC2*      114               −1.033286429      0.101896116
  cg05564657   chr3         153014065                    *AADAC*      486               −1.018512857      −0.054630151
  cg06866657   chr9         124030575                    *LHX6*       230               −1.000721071      0.437413369
  cg08831744   chr7         45927871                     *IGFBP3*     475               1.023873571       0.456738536
  cg03462055   chr6         3172555                      *TUBB2B*     315               1.175827143       0.725177791
  cg00910067   chr19        38409385                     *SLC7A10*    837               1.289525714       0.253285976
  cg05976074   chr19        38408113                     *SLC7A10*    435               1.289525714       0.380324218
  cg14546153   chr20        56523721                     *FLJ90166*   366               1.331159286       0.43120249
  cg00616129   chr12        10718281                     *STYK1*      375               1.541281786       −0.209664965
  cg23582408   chr20        61600555                     *EEF1A2*     394               2.431418571       0.497897542

Note: IllumID represents probe name. Meth.pos stands for the position of methylation site in genome. Distance_to_TSS indicates the distance of methylation site from transcriptional start site of downstream gene. *β* in log~2~⁡FC⁡(β) represents methylation index of methylation probe.
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